Time course effects of lithium administration on spatial memory acquisition and cholinergic marker expression in rats

Daru

Volumn 17, Issue 2, 2009, Pages 113-123

  Karimfar, M H ^a   Tabrizian, K ^b   Azami, K ^b   Hosseini Sharifabad, A ^b   Hoseini, A ^b   Pourghorban, M ^b   Aghsami, M ^b   Gholizadeh, S ^b   Abdollahi, M ^b   Roghani, A ^c,d   Sharifzadeh, M ^b  

^a ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d TEXAS TECH UNIVERSITY   (United States)

Author keywords

Cholinacetyltransferase; Lithium; Medial septal nucleus; Morris water maze; Spatial memory

Indexed keywords

CHOLINE ACETYLTRANSFERASE; LITHIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN NERVE CELL; BRAIN TISSUE; CELL DENSITY; CONTROLLED STUDY; ESCAPE BEHAVIOR; LATENT PERIOD; LITHIUM BLOOD LEVEL; LONG TERM CARE; MALE; MAZE TEST; NONHUMAN; RAT; SEPTUM NUCLEUS; SPATIAL MEMORY; SWIMMING; VELOCITY;

EID: 68949103408     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Shaldubina A, Agam G, Belmaker RH. The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 855-866. (Pubitemid 32374970)
2. Vestergaard P, Licht RW. 50 Years with lithium treatment in affective disorders: present problems and priorities. World J Biol Psychiatry 2001; 2: 18-26.
3. Chaudhary G, Gupta YK. Lithium does not synergize the peripheral action of cholinomimetics as seen in the central nervous system. Life Sci 2001; 68: 2115-2121. (Pubitemid 32289393)
4. Ahluwalia P, Singhal RL. Comparison of the changes in central catecholamine systems following short- and long-term lithium treatment and the consequences of lithium withdrawal. Neuropsychobiology 1984; 12: 217-223. (Pubitemid 15111411)
5. Al Banchaabouchi M, Pena de Ortiz S, Menendez R, Ren K, Maldonado-Vlaar CS. Chronic lithium decreases Nurr1 expression in the rat brain and impairs spatial discrimination. Pharmacol Biochem Behav 2004; 79: 607-621. (Pubitemid 39600601)
6. Odagaki Y, Koyama T, Matsubara S, Matsubara R, Yamashita I. Effects of chronic lithium treatment on serotonin binding sites in rat brain. J Psychiatr Res 1990; 24: 271-277. (Pubitemid 20347111)
7. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328-1351.
8. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995; 52: 531-543.
9. Creson TK, Woodruff ML, Ferslew KE, Rasch EM, Monaco PJ. Dose-response effects of chronic lithium regimens on spatial memory in the black molly fish. Pharmacol Biochem Behav 2003; 75: 35-47.
10. Christodoulou GN, Kokkevi A, Lykouras EP, Stefanis CN, Papadimitriou GN. Effects of lithium on memory. Am J Psychiatry 1981; 138: 847-848.
11. Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology Berl. 2003; 170: 225-234.
12. Reus VI, Targum SD, Weingarter H, Post RM. Effect of lithium carbonate on memory processes of bipolar affectively ill patients. Psychopharmacology Berl. 1979; 63: 39-42.
13. Shaw ED, Stokes PE, Mann JJ, Manevitz AZ. Effects of lithium carbonate on the memory and motor speed of bipolar outpatients. J Abnorm Psychol 1987; 96: 64-69.
14. Stip E, Dufresne J, Lussier I, Yatham L. A double-blind, placebo-controlled study of the effects of lithium on cognition in healthy subjects: mild and selective effects on learning. J Affect Disord 2000; 60: 147-157. (Pubitemid 30829576)
15. Sharma I, Singh P. Cognitive functions in patients of primary affective disorder on prophylactic lithium treatment. Indian J Med Res 1988; 88: 246-252. (Pubitemid 18267965)
16. Squire LR, Judd LL, Janowsky DS, Huey LY. Effects of lithium carbonate on memory and other cognitive functions. Am J Psychiatry 1980; 137: 1042-1046.
17. Acquas E, Fibiger HC. Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex. Psychopharmacology Berl. 1996; 125: 162-167. (Pubitemid 26173186)
18. Bosetti F, Seemann R, Bell JM, Zahorchak R, Friedman E, Rapoport SI et al. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res Bull 2002; 57: 205-209. (Pubitemid 34155394)
19. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004; 16: 83-90.
20. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev 2004; 47: 275-289. (Pubitemid 39574325)
21. Fujii T, Nakai K, Nakajima Y, Kawashima K. Enhancement of hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by repeated lithium treatment in rats. Can J Physiol Pharmacol 2000; 78: 392-399. (Pubitemid 30354462)
22. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997; 185: 82-91. (Pubitemid 27244219)
23. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668. (Pubitemid 27050234)
24. Tanaka T. Effects of chronic lithium treatment on spatial memory formation in rats: involvement with an increased expression of dopamine D1 receptors in the rat frontal cortex.. Hokkaido Igaku Zasshi 2004; 79: 55-64.
25. Wu CL, Huang LT, Liou CW, Wang TJ, Tung YR, Hsu HY et al. Lithium-pilocarpine-induced status epilepticus in immature rats result in long-term deficits in spatial learning and hippocampal cell loss. Neurosci Lett 2001; 312: 113-117.
26. Descarries L, Aznavour N, Hamel E. The acetylcholine innervation of cerebral cortex: new data on its normal development and its fate in the hAPPSW,IND. mouse model of Alzheimer's disease. J Neural Transm 2005; 112: 149-162. (Pubitemid 40104725)
27. Hasselmo ME, McGaughy J. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog Brain Res 2004; 145: 207-231. (Pubitemid 37442946)
28. Beach TG, Kuo YM, Spiegel K, Emmerling MR, Sue LI, Kokjohn K et al. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 308-313. (Pubitemid 30183698)
29. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403. (Pubitemid 8004505)
30. Geula C, Mesulam MM. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 1996; 6: 165-177. (Pubitemid 26117394)
31. Mufson EJ, Ma SY, Dills J, Cochran EJ, Leurgans S, Wuu J et al. Loss of basal forebrain P75NTR. immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2002; 443: 136-153. (Pubitemid 34052063)
32. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-126.
33. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002; 68: 209-245. (Pubitemid 35346805)
34. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749-760.
35. Riekkinen P, Jr., Sirvio J, Aaltonen M, Riekkinen P. Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol Biochem Behav 1990; 37: 405-410.
36. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000; 48: 194-200. (Pubitemid 30617038)
37. Ichikawa T, Ajiki K, Matsuura J, Misawa H. Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: in situ hybridization histochemistry and immunohistochemistry. J Chem Neuroanat 1997; 13: 23-39. (Pubitemid 27358988)
38. Roghani A, Shirzadi A, Butcher LL, Edwards RH. Distribution of the vesicular transporter for acetylcholine in the rat central nervous system. Neuroscience 1998; 82: 1195-1212. (Pubitemid 27502061)
39. Waite JJ, Chen AD, Wardlow ML, Thal LJ. Behavioral and biochemical consequences of combined lesions of the medial septum/diagonal band and nucleus basalis in the rat when ibotenic acid, quisqualic acid, and AMPA are used. Exp Neurol 1994; 130: 214-229.
40. Hiramatsu M, Yamatsu T, Kameyama T, Nabeshima T. Effects of repeated administration of -.- nicotine on AF64A-induced learning and memory impairment in rats. J Neural Transm 2002; 109: 361-375. (Pubitemid 34251639)
41. Sharifzadeh M, Sharifzadeh K, Naghdi N, Ghahremani MH, Roghani A. Posttraining intrahippocampal infusion of a protein kinase AII inhibitor impairs spatial memory retention in rats. J Neurosci Res 2005; 79: 392-400. (Pubitemid 40278354)
42. Basselin M, Chang L, Seemann R, Bell JM, Rapoport SI. Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats. J Neurochem 2003; 85: 1553-1562. (Pubitemid 36702567)
43. Evans MS, Zorumski CF, Clifford DB. Lithium enhances neuronal muscarinic excitation by presynaptic facilitation. Neuroscience 1990; 38: 457-468.
44. Jope R. Effects of lithium treatment in vitro and in vivo on acetylcholine metabolism in rat brain. J Neurochem 1979; 33: 487-495. (Pubitemid 9240936)
45. Woolf NJ, Milov AM, Schweitzer ES, Roghani A. Elevation of nerve growth factor and antisense knockdown of TrkA receptor during contextual memory consolidation. J Neurosci 2001; 21: 1047-1055. (Pubitemid 32163145)
46. Vasconcellos AP, Tabajara AS, Ferrari C, Rocha E, Dalmaz C. Effect of chronic stress on spatial memory in rats is attenuated by lithium treatment. Physiol Behav 2003; 79: 143-149. (Pubitemid 36776665)
47. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology Berl. 2001; 158: 100-106. (Pubitemid 32938319)
48. Hashimoto R, Fujimaki K, Jeong MR, Senatorov VV, Christ L, Leeds P et al. Neuroprotective actions of lithium.. Seishin Shinkeigaku Zasshi 2003; 105: 81-86.
49. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9: 2081-2084. (Pubitemid 28300570)
50. Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y et al. Lithium suppresses excitotoxicityinduced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001; 106: 603-612. (Pubitemid 32925248)
51. Liles WC, Nathanson NM. Alteration in the regulation of neuronal muscarinic acetylcholine receptor number induced by chronic lithium in neuroblastoma cells. Brain Res 1988; 439: 88-94.
52. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S et al. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 2002; 11: 257-274. (Pubitemid 36135690)
53. Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of betaamyloid and prion proteins. J Neurosci 1999; 19: 928-939.
54. McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 1997; 17: 2284-2294.
55. Wood JG, Zinsmeister P. Tyrosine phosphorylation systems in Alzheimer's disease pathology. Neurosci Lett 1991; 121: 12-16.
56. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X et al. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 1999; 72: 2053-2058. (Pubitemid 29186010)
57. Van der Zee CE, Lourenssen S, Stanisz J, Diamond J. NGF deprivation of adult rat brain results in cholinergic hypofunction and selective impairments in spatial learning. Eur J Neurosci 1995; 7: 160-168.
58. Fischer W, Sirevaag A, Wiegand SJ, Lindsay RM, Bjorklund A. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brainderived neurotrophic factor. Proc Natl Acad Sci U S A 1994; 91: 8607-8611. (Pubitemid 24273713)
59. Janis LS, Glasier MM, Martin G, Stackman RW, Walsh TJ, Stein DG. A single intraseptal injection of nerve growth factor facilitates radial maze performance following damage to the medial septum in rats. Brain Res 1995; 679: 99-109.
60. Markowska AL, Price D, Koliatsos VE. Selective effects of nerve growth factor on spatial recent memory as assessed by a delayed nonmatching-to-position task in the water maze. J Neurosci 1996; 16: 3541-3548. (Pubitemid 26142383)
61. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
62. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21: 679-682. (Pubitemid 29486636)